Evidence map›Paper›PMID 26912618›Full record

ArticleJournal of virology2016

APOBEC3G and APOBEC3F Act in Concert To Extinguish HIV-1 Replication.

John F Krisko, Nurjahan Begum, Caroline E Baker, John L Foster, J Victor Garcia

Open access · bronzeAbstract read
In one paragraph

Article in Journal of virology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Molecular Biology and Diversification of Human Retroviruses.Frontiers in virology (Lausanne, Switzerland) · 2022
    Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Human Primary Macrophages DerivedFrontiers in immunology · 2017
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

John F KriskoDivision of Infectious Diseases, Center for AIDS Research, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA.
Nurjahan BegumDivision of Infectious Diseases, Center for AIDS Research, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA.
Caroline E BakerDivision of Infectious Diseases, Center for AIDS Research, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA.
John L FosterDivision of Infectious Diseases, Center for AIDS Research, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA victor_garcia@med.unc.edu john_foster@med.unc.edu.
J Victor GarciaDivision of Infectious Diseases, Center for AIDS Research, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA victor_garcia@med.unc.edu john_foster@med.unc.edu.
University of North Carolina at Chapel Hill · US

Funding

Virology Research Program (Program 4)P30CA016086 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Deborah F. Tate · 1985 to 2026
$201.5M
Virology, Immunology, and Microbiology CoreP30AI050410 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAVID M. MARGOLIS · 2001 to 2026
$76.9M
NEF FUNCTIONR01AI033331 · NIAID · UT SOUTHWESTERN MEDICAL CENTER · PI GARCIA-MARTINEZ, J. VICTOR · 1994 to 2010
$4.4M
Next Generation Pre-exposure ProphylaxisR01AI096138 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI GARCIA-MARTINEZ, J. VICTOR · 2011 to 2014
$3.5M
Towards therapy-induced lethal HIV mutagenesisR21AI096937 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI GARCIA-MARTINEZ, J. VICTOR · 2011 to 2012
$495k
NCI NIH HHS P30 CA016086NIAID NIH HHS AI033331NIAID NIH HHS AI096937NIAID NIH HHS AI96138NIAID NIH HHS P30 AI050410NIAID NIH HHS P30 AI50410NIAID NIH HHS R01 AI033331NIAID NIH HHS R01 AI096138NIAID NIH HHS R21 AI096937
6 · The paper itself

Abstract

unlabelledThe multifunctional HIV-1 accessory protein Vif counters the antiviral activities of APOBEC3G (A3G) and APOBEC3F (A3F), and some Vifs counter stable alleles of APOBEC3H (A3H). Studies in humanized mice have shown that HIV-1 lacking Vif expression is not viable. Here, we look at the relative contributions of the three APOBEC3s to viral extinction. Inoculation of bone marrow/liver/thymus (BLT) mice with CCR5-tropic HIV-1JRCSF(JRCSF) expressing a vif gene inactive for A3G but not A3F degradation activity (JRCSFvifH42/43D) displayed either no or delayed replication. JRCSF expressing a vif gene mutated to inactivate A3F degradation but not A3G degradation (JRCSFvifW79S) always replicated to high viral loads with variable delays. JRCSF with vif mutated to lack both A3G and A3F degradation activities (JRCSFvifH42/43DW79S) failed to replicate, mimicking JRCSF without Vif expression (JRCSFΔvif). JRCSF and JRCSFvifH42/43D, but not JRCSFvifW79S or JRCSFvifH42/43DW79S, degraded APOBEC3D. With one exception, JRCSFs expressing mutant Vifs that replicated acquired enforced vif mutations. These mutations partially restored A3G or A3F degradation activity and fully replaced JRCSFvifH42/43D or JRCSFvifW79S by 10 weeks. Surprisingly, induced mutations temporally lagged behind high levels of virus in blood. In the exceptional case, JRCSFvifH42/43D replicated after a prolonged delay with no mutations in vif but instead a V27I mutation in the RNase H coding sequence. JRCSFvifH42/43D infections exhibited massive GG/AG mutations in pol viral DNA, but in viral RNA, there were no fixed mutations in the Gag or reverse transcriptase coding sequence. A3H did not contribute to viral extinction but, in combination with A3F, could delay JRCSF replication. A3H was also found to hypermutate viral DNA. IMPORTANCE: Vif degradation of A3G and A3F enhances viral fitness, as virus with even a partially restored capacity for degradation outgrows JRCSFvifH42/43D and JRCSFvifW79S. Unexpectedly, fixation of mutations that replaced H42/43D or W79S in viral RNA lagged behind the appearance of high viral loads. In one exceptional JRCSFvifH42/43D infection, vif was unchanged but replication proceeded after a long delay. These results suggest that Vif binds and inhibits the non-cytosine deaminase activities of intact A3G and intact A3F, allowing JRCSFvifH42/43D and JRCSFvifW79S to replicate with reduced fitness. Subsequently, enhanced Vif function is acquired by enforced mutations. In infected cells, JRCSFΔvif and JRCSFvifH42/43DW79S are exposed to active A3F and A3G and fail to replicate. JRCSFvifH42/43D Vif degrades A3F and, in some cases, overcomes A3G mutagenic activity to replicate. Vif may have evolved to inhibit A3F and A3G by stoichiometric binding and subsequently acquired the ability to target these proteins to proteasomes.

Indexed as

Virus ReplicationAllelesAminohydrolasesAnimalsAPOBEC-3G DeaminaseBase SequenceCell LineCytidine DeaminaseCytosine DeaminaseDisease Models, AnimalDNA Mutational AnalysisDNA, ViralGene AmplificationHaplotypesHIV-1HIV InfectionsAminohydrolasesAPOBEC3F protein, humanAPOBEC-3G DeaminaseAPOBEC3G protein, humanAPOBEC3H protein, humanCytidine DeaminaseCytosine DeaminaseDNA, Viralvif Gene Products, Human Immunodeficiency Virusvif protein, Human immunodeficiency virus 1

Identifiers

PMID26912618
PMCPMC4836340
OpenAlexW2283305877

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.